<DOC>
	<DOCNO>NCT01309945</DOCNO>
	<brief_summary>The purpose study evaluate efficacy study drug ( BMS-820836 ) compare continued duloxetine treatment patient treatment resistant depression ( TRD ) .</brief_summary>
	<brief_title>Efficacy Safety Flexibly Dosed BMS-820836 Treatment Patients With Treatment Resistant Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Patients must able understand nature study , agree comply prescribed dosage regimen , report regularly schedule office visit , communicate study personnel adverse event concomitant medication use . Patients diagnosis Major Depressive Disorder , currently experience Major Depressive Episode , define Diagnostic Statistical Manual Mental Disorders Fourth Edition Text Revision ( DSM IV TR ) criterion . The current depressive episode must &gt; 8 week duration &lt; 3 year duration . In current Major Depressive Disorder ( MDD ) episode , patient report history inadequate response 1 3 adequate trial antidepressant treatment . Patients must 17item Hamilton Depression Rating Scale ( HAMD17 ) total score = &gt; 18 Screening . Patients report inadequate response ( le 50 % reduction depressive symptom severity ) three adequate trial antidepressant treatment current depressive episode . Patients fail duloxetine adequate dose adequate duration current episode unless judgment investigator , patient could benefit treatment medication . Patients whose inadequate response antidepressant current Major Depressive Episode ( MDE ) Serotonin norepinephrine reuptake inhibitor ( SNRI ) ( duloxetine , venlafaxine , desvenlafaxine milnacipran ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>